| Heading: |
NHS: Drugs |
| Question ID: |
1826515 |
| UIN: |
HL9906 |
| House: |
Lords |
| Date tabled: |
2025-07-24 |
| Asking Member ID: |
2484 |
| Asking Member display name: |
Lord Rennard
|
| Asking Member handle: |
LordRennard
|
| Asking Member Twitter reference: |
@LordRennard
|
| Member interest: |
false |
| Question text: |
To ask His Majesty's Government what assessment they have made of adopting reimbursed access at the point of marking authorisation for medicines; and what assessment they have made of the impact of cost-effectiveness appraisals after real world use on the |
| Is named day: |
false |
| Date of holding answer: |
|
| Date answered: |
2025-08-04 |
| Date answer corrected: |
|
| Is holding answer: |
false |
| Is correcting answer: |
false |
| Answering Member ID: |
347 |
| Answering Member display name: |
Baroness Merron
|
| Answering Member handle: |
|
| Answering Member Twitter reference: |
Baroness Merron
|
| Correcting Member ID: |
|
| Correcting Member display name: |
|
| Correcting Member handle: |
|
| Correcting Member Twitter reference: |
|
| Answer text: |
The Government wants National Health Service patients in England to be able to benefit from rapid access to effective new medicines. The National Institute for Health and Care Excellence (NICE) evaluates all new licensed medicines and makes recommendation... |
| Original answer text: |
|
| Comparable answer text: |
|
| Answering body ID: |
17 |
| Answering body name: |
Department of Health and Social Care |
| Tweeted: |
true |